author-photo

Craig W. Reynolds

National Institutes of Health

110

Papers

6095

Citations

Citation Trend

Filter By

Papers (110) Sort By

JournalConferenceOthers

Phase 1/2 Study of the Safety and Tolerability of Nivolumab Plus Crizotinib for the First-Line Treatment of Anaplastic Lymphoma Kinase Translocation — Positive Advanced Non–Small Cell Lung Cancer (CheckMate 370)

2018 Journal of Thoracic Oncology
Show All
- Source
- Cite
- Save
Citations (117)
Real-World Use and Outcomes of ALK-Positive Crizotinib-Treated Metastatic NSCLC in US Community Oncology Practices: A Retrospective Observational Study

2018 Journal of Clinical Medicine
Show All
- Source
- Cite
- Save
Citations (6)
P3.02a-019 Real World Utilization and Outcomes of ALK-Positive Crizotinib Treated Metastatic NSCLC Patients in US Community Oncology Practice: Topic: ALK Clinical

2017 Journal of Thoracic Oncology
Show All
- Source
- Cite
- Save
Citations (1)
P3.02c-026 Is Nivolumab Safe and Effective in Elderly and PS2 Patients with Non-Small Cell Lung Cancer (NSCLC)? Results of CheckMate 153: Topic: IT

2017 Journal of Thoracic Oncology
Show All
- Source
- Cite
- Save
Citations (37)
Final Results of a Phase 1/2 Open-Label Study to Assess the Safety, Tolerability and Preliminary Efficacy of Evofosfamide, a Hypoxia-Activated Prodrug, and Dexamethasone with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma

2016 Blood
Show All
- Source
- Cite
- Save
Citations (1)
PS01.59: CheckMate 370: A Master Protocol of Phase 1/2 Studies of Nivolumab as Maintenance or First-Line ± Standard-of-Care Therapies in Advanced NSCLC: Topic: Medical Oncology

2016 Journal of Thoracic Oncology
Show All
- Source
- Cite
- Save
Citations (2)
A Phase 1/2 Trial of TH-302 and Dexamethasone without or with Bortezomib (TBorD) in Patients with Relapsed/Refractory Multiple Myeloma

2014 Blood
Show All
- Source
- Cite
- Save
Citations (3)
Natural killer activity: early days, advances, and seminal observations.

2014 Critical Reviews in Oncogenesis
Show All
- Source
- Cite
- Save
Citations (5)
Docetaxel or pemetrexed with or without cetuximab in recurrent or progressive non-small-cell lung cancer after platinum-based therapy: a phase 3, open-label, randomised trial

2013 Lancet Oncology
Show All
- Source
- Cite
- Save
Citations (59)
Erratum: Sunitinib malate in previously untreated, nonsquamous, non-small cell lung cancer patients over the age of 70 years: Results of a Phase II trial (Investigational New Drugs DOI:10.1007/s10637-013-9985-0))

2013 Investigational New Drugs
Show All
- Source
- Cite
- Save
Citations (0)

© Copyright 2015-2020 Acemap, Inc. Shanghai Jiao Tong University.

沪ICP备18028330号